61 related articles for article (PubMed ID: 38429756)
21. Apigenin Inhibits IL-6 Transcription and Suppresses Esophageal Carcinogenesis.
Qiu JG; Wang L; Liu WJ; Wang JF; Zhao EJ; Zhou FM; Ji XB; Wang LH; Xia ZK; Wang W; Lin MC; Liu LZ; Huang YX; Jiang BH
Front Pharmacol; 2019; 10():1002. PubMed ID: 31572184
[TBL] [Abstract][Full Text] [Related]
22. Recent progress in multidisciplinary treatment for patients with esophageal cancer.
Watanabe M; Otake R; Kozuki R; Toihata T; Takahashi K; Okamura A; Imamura Y
Surg Today; 2020 Jan; 50(1):12-20. PubMed ID: 31535225
[TBL] [Abstract][Full Text] [Related]
23. Haspin knockdown can inhibit progression and development of pancreatic cancer in vitro and vivo.
Han X; Kuang T; Ren Y; Lu Z; Liao Q; Chen W
Exp Cell Res; 2019 Dec; 385(1):111605. PubMed ID: 31493385
[TBL] [Abstract][Full Text] [Related]
24. PHD finger protein 5A promoted lung adenocarcinoma progression via alternative splicing.
Mao S; Li Y; Lu Z; Che Y; Huang J; Lei Y; Wang Y; Liu C; Wang X; Zheng S; Sun N; He J
Cancer Med; 2019 May; 8(5):2429-2441. PubMed ID: 30932358
[TBL] [Abstract][Full Text] [Related]
25. Systemic treatment of advanced esophageal squamous cell carcinoma: chemotherapy, molecular-targeting therapy and immunotherapy.
Hirano H; Kato K
Jpn J Clin Oncol; 2019 May; 49(5):412-420. PubMed ID: 30920626
[TBL] [Abstract][Full Text] [Related]
26. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Bray F; Ferlay J; Soerjomataram I; Siegel RL; Torre LA; Jemal A
CA Cancer J Clin; 2018 Nov; 68(6):394-424. PubMed ID: 30207593
[TBL] [Abstract][Full Text] [Related]
27. Dihydroartemisinin Increases the Sensitivity of Photodynamic Therapy Via NF-κB/HIF-1α/VEGF Pathway in Esophageal Cancer Cell in vitro and in vivo.
Li Y; Sui H; Jiang C; Li S; Han Y; Huang P; Du X; Du J; Bai Y
Cell Physiol Biochem; 2018; 48(5):2035-2045. PubMed ID: 30099443
[TBL] [Abstract][Full Text] [Related]
28. ANXA2 promotes esophageal cancer progression by activating MYC-HIF1A-VEGF axis.
Ma S; Lu CC; Yang LY; Wang JJ; Wang BS; Cai HQ; Hao JJ; Xu X; Cai Y; Zhang Y; Wang MR
J Exp Clin Cancer Res; 2018 Aug; 37(1):183. PubMed ID: 30081903
[TBL] [Abstract][Full Text] [Related]
29. PHF5A Epigenetically Inhibits Apoptosis to Promote Breast Cancer Progression.
Zheng YZ; Xue MZ; Shen HJ; Li XG; Ma D; Gong Y; Liu YR; Qiao F; Xie HY; Lian B; Sun WL; Zhao HY; Yao L; Zuo WJ; Li DQ; Wang P; Hu X; Shao ZM
Cancer Res; 2018 Jun; 78(12):3190-3206. PubMed ID: 29700004
[TBL] [Abstract][Full Text] [Related]
30. PHD-finger domain protein 5A functions as a novel oncoprotein in lung adenocarcinoma.
Yang Y; Zhu J; Zhang T; Liu J; Li Y; Zhu Y; Xu L; Wang R; Su F; Ou Y; Wu Q
J Exp Clin Cancer Res; 2018 Mar; 37(1):65. PubMed ID: 29566713
[TBL] [Abstract][Full Text] [Related]
31. Epigenetics at the base of alternative splicing changes that promote colorectal cancer.
Kornblihtt AR
J Clin Invest; 2017 Sep; 127(9):3281-3283. PubMed ID: 28825597
[TBL] [Abstract][Full Text] [Related]
32. Histone methyltransferase SETD2 modulates alternative splicing to inhibit intestinal tumorigenesis.
Yuan H; Li N; Fu D; Ren J; Hui J; Peng J; Liu Y; Qiu T; Jiang M; Pan Q; Han Y; Wang X; Li Q; Qin J
J Clin Invest; 2017 Sep; 127(9):3375-3391. PubMed ID: 28825595
[TBL] [Abstract][Full Text] [Related]
33. Oncogenic Roles of the PI3K/AKT/mTOR Axis.
Aoki M; Fujishita T
Curr Top Microbiol Immunol; 2017; 407():153-189. PubMed ID: 28550454
[TBL] [Abstract][Full Text] [Related]
34. Splicing modulators act at the branch point adenosine binding pocket defined by the PHF5A-SF3b complex.
Teng T; Tsai JH; Puyang X; Seiler M; Peng S; Prajapati S; Aird D; Buonamici S; Caleb B; Chan B; Corson L; Feala J; Fekkes P; Gerard B; Karr C; Korpal M; Liu X; T Lowe J; Mizui Y; Palacino J; Park E; Smith PG; Subramanian V; Wu ZJ; Zou J; Yu L; Chicas A; Warmuth M; Larsen N; Zhu P
Nat Commun; 2017 May; 8():15522. PubMed ID: 28541300
[TBL] [Abstract][Full Text] [Related]
35. Esophageal cancer: Risk factors, genetic association, and treatment.
Huang FL; Yu SJ
Asian J Surg; 2018 May; 41(3):210-215. PubMed ID: 27986415
[TBL] [Abstract][Full Text] [Related]
36. Clinicopathological and prognostic significance of mTOR and phosphorylated mTOR expression in patients with esophageal squamous cell carcinoma: a systematic review and meta-analysis.
Li S; Wang Z; Huang J; Cheng S; Du H; Che G; Peng Y
BMC Cancer; 2016 Nov; 16(1):877. PubMed ID: 27835987
[TBL] [Abstract][Full Text] [Related]
37. Regulation of transcriptional elongation in pluripotency and cell differentiation by the PHD-finger protein Phf5a.
Strikoudis A; Lazaris C; Trimarchi T; Galvao Neto AL; Yang Y; Ntziachristos P; Rothbart S; Buckley S; Dolgalev I; Stadtfeld M; Strahl BD; Dynlacht BD; Tsirigos A; Aifantis I
Nat Cell Biol; 2016 Nov; 18(11):1127-1138. PubMed ID: 27749823
[TBL] [Abstract][Full Text] [Related]
38. Targeted Therapies for Advanced Oesophagogastric Cancer: Recent Progress and Future Directions.
Young K; Chau I
Drugs; 2016 Jan; 76(1):13-26. PubMed ID: 26620367
[TBL] [Abstract][Full Text] [Related]
39. A validated miRNA profile predicts response to therapy in esophageal adenocarcinoma.
Skinner HD; Lee JH; Bhutani MS; Weston B; Hofstetter W; Komaki R; Shiozaki H; Wadhwa R; Sudo K; Elimova E; Song S; Ye Y; Huang M; Ajani J; Wu X
Cancer; 2014 Dec; 120(23):3635-41. PubMed ID: 25091571
[TBL] [Abstract][Full Text] [Related]
40. Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial.
Dutton SJ; Ferry DR; Blazeby JM; Abbas H; Dahle-Smith A; Mansoor W; Thompson J; Harrison M; Chatterjee A; Falk S; Garcia-Alonso A; Fyfe DW; Hubner RA; Gamble T; Peachey L; Davoudianfar M; Pearson SR; Julier P; Jankowski J; Kerr R; Petty RD
Lancet Oncol; 2014 Jul; 15(8):894-904. PubMed ID: 24950987
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
